Moderna, a biotechnology company, is expanding its mRNA technology. The makers of the Spikevax COVID -19 vaccine are now working on two more vaccines: one to protect against SARS-CoV-2, influenza and respiratory syncytial virus (RSV), and another to protect against the four endogenous human coronaviruses that can cause the common cold. common. Therefore, check out this article for information on the development of vaccines to protect against the common cold.
Read more: Can the Coronavirus Cause Other Diseases Besides Covid-19: Myth or Truth?
see more
Google develops AI tool to help journalists in…
Unopened original 2007 iPhone sells for nearly $200,000; know...
Advances in research for cold vaccine production
According to a press release from Moderna, the new vaccines – for which development programs have just been launched – aim to reduce the impact that respiratory viruses have on public health, especially among the elderly, who are more susceptible to disease serious.
According to data collected in the United States, the population of that country is aging and it is not difficult to predict that cold viruses will exert an increasing amount of unpredictability on our seniors, particularly those who live in nursing homes. health. However, this predictability can be observed in many other countries around the world, including Brazil.
about vaccines
Given the safety and efficacy of mRNA COVID-19 vaccines, particularly in older adults, the good news is that the companies that made them are working on new programs to treat other viral respiratory infections.
The first of two vaccines Moderna is working on is a three-in-one respiratory vaccine candidate, known as mRNA-1230, for now. The idea is that it is an annual booster, used to protect against SARS-CoV-2, influenza and RSV. These are the three most significant viruses that cause breathing problems in older adults.
The second vaccine proposed by Moderna is intended to protect against four endemic human coronaviruses (HCoVs), which together they account for 10-30% of respiratory illnesses from infections that are treatable worldwide, according to the company. In theory, this vaccine protects against some but not all common cold causes.
